APA (7th ed.) Citation

EF, M., VP, W., J, W., R, F., M, D., J, S., . . . DR, P. (2026). Efficacy and safety of enpatoran, a Toll-like receptor 7/8 inhibitor, in patients with skin manifestations of cutaneous lupus erythematosus or systemic lupus erythematosus: Findings from Cohort A of a multicentre, international, double-blind, placebo-controlled, dose-finding phase 2 trial. The Lancet. Rheumatology, 8(7), e513. https://doi.org/10.1016/S2665-9913(25)00337-6

Chicago Style (17th ed.) Citation

EF, Morand, et al. "Efficacy and Safety of Enpatoran, a Toll-like Receptor 7/8 Inhibitor, in Patients with Skin Manifestations of Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus: Findings from Cohort A of a Multicentre, International, Double-blind, Placebo-controlled, Dose-finding Phase 2 Trial." The Lancet. Rheumatology 8, no. 7 (2026): e513. https://doi.org/10.1016/S2665-9913(25)00337-6.

MLA (9th ed.) Citation

EF, Morand, et al. "Efficacy and Safety of Enpatoran, a Toll-like Receptor 7/8 Inhibitor, in Patients with Skin Manifestations of Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus: Findings from Cohort A of a Multicentre, International, Double-blind, Placebo-controlled, Dose-finding Phase 2 Trial." The Lancet. Rheumatology, vol. 8, no. 7, 2026, p. e513, https://doi.org/10.1016/S2665-9913(25)00337-6.